-
4
-
Korean J Hepatol. 2008;14(4):513-518. Published online December 31, 2008.
DOI: https://doi.org/10.3350/kjhep.2008.14.4.513
- A case report of treatment with pegylated interferon alpha for Lamivudine-resistant chronic hepatitis B virus infection
-
-
- Abstract
- The wide use of lamivudine in chronic hepatitis B has produced a monotonic increase in patients with lamivudine resistance. Therefore, treating lamivudine resistance in chronic hepatitis B is a major concern in clinical practice for the treatment of hepatitis B virus (HBV). There is conflicting evidence on the outcome of pegylated interferon alpha (PEG-IFN α) therapy against lamivudine-resistant HBV, which is due to mutations in the YMDD motif. We experienced a patient with chronic hepatitis B who was successfully treated with PEG-IFN α-2a after the development of virologic and biochemical breakthrough during lamivudine therapy. Virologic breakthrough was associated with the emergence of YMDD mutants 48 months after starting lamivudine therapy. Treatment with PEG-IFN α-2a for 12 months resulted in an undetectable serum level of HBV DNA and the resolution of hepatitis, and the virologic response was maintained over 16 months after cessation of PEG-IFN α-2a. (Korean J Hepatol 2008;14:513-518)
Keywords :Pegylated interferon alfa-2a; Lamivudine; YMDD motif mutant; Hepatitis B, Chronic
